[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Masatomo
M
Miura
Naoto
N
Takahashi
D001549:Benzamides / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib